350 related articles for article (PubMed ID: 31488409)
1. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract][Full Text] [Related]
5. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Fischer K; Al-Sawaf O; Fink AM; Dixon M; Bahlo J; Warburton S; Kipps TJ; Weinkove R; Robinson S; Seiler T; Opat S; Owen C; López J; Humphrey K; Humerickhouse R; Tausch E; Frenzel L; Eichhorst B; Wendtner CM; Stilgenbauer S; Langerak AW; van Dongen JJM; Böttcher S; Ritgen M; Goede V; Mobasher M; Hallek M
Blood; 2017 May; 129(19):2702-2705. PubMed ID: 28325865
[No Abstract] [Full Text] [Related]
7. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
8. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
13. Is there a role for anti-CD20 antibodies in CLL?
Shah HR; Stephens DM
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
[TBL] [Abstract][Full Text] [Related]
14. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
15. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
[TBL] [Abstract][Full Text] [Related]
16. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Salvaris R; Opat S
Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.
Blair HA
Drugs; 2020 Dec; 80(18):1973-1980. PubMed ID: 33201424
[TBL] [Abstract][Full Text] [Related]
19. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.
Fischer K; Al-Sawaf O; Hallek M
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):357-362. PubMed ID: 33275717
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
